Promega - caspase-GLO(R) 3/7 assay, 100ML - catalog #G8092 - for anton simeonov
Ended Awarded
- Contract number
- HHSN31900001
- Awardee
-
Promega Corporation UEI MWM4N9L4S5X4
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $18,761
Award facts
- Contract value 100% obligated
- $18,761.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Madison, WI 53711, USA
Award details come from SAM.gov/FPDS.
About this award
Promega Corporation was awarded a firm fixed price Blanket Purchase Agreement (BPA) call valued at $18,761.20 by the National Center for Advancing Translational Sciences (NCATS) on July 21, 2014. The contract involves the procurement of Caspase-Glo® 3/7 Assay reagent kits (100 mL, catalog #G8092) for Anton Simeonov, with performance completed in Madison, Wisconsin. This award was not designated as a small business set-aside, reflecting Promega's status as a large, for-profit life sciences manufacturer capable of meeting complex federal research requirements.
This BPA call was issued under Promega's existing $10 million Blanket Purchase Agreement with the National Institutes of Health's Office of Logistics and Acquisition Operations, which covers biological materials, chemicals, medical and scientific equipment, and maintenance services. NCATS, a division of NIH, focuses on translational research initiatives to accelerate the development of diagnostics and therapeutics. The Caspase-Glo® 3/7 Assay is a luminescent cell viability and apoptosis detection assay commonly used in drug discovery and biomedical research applications, supporting NCATS's mission to advance scientific research capabilities across the federal research enterprise.
Quick answers
Who was awarded contract HHSN31900001?
HHSN31900001 was awarded to Promega Corporation by National Center for Advancing Translational Sciences (National Institutes of Health) on July 21, 2014.
How much is contract HHSN31900001 worth?
The government has obligated $18,761 on HHSN31900001.
Is contract HHSN31900001 an order under another contract?
Yes. HHSN31900001 is a BPA call under HHSN263199900051808B, a blanket purchase agreement.
Was contract HHSN31900001 competed?
The extent of competition for HHSN31900001 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award